



E-ISSN: 2278-4136

P-ISSN: 2349-8234

[www.phytojournal.com](http://www.phytojournal.com)

JPP 2020; 9(2): 1259-1264

Received: 04-01-2020

Accepted: 06-02-2020

**Ashish Pandey**

M. V. Sc., Department of  
Veterinary Medicine, C. V. Sc. & A.  
H., A.N.D. University of  
Agriculture & Technology,  
Kumarganj, Ayodhya,  
Uttar Pradesh, India

**Satya Vrat Singh**

Assistant Professor, Department of  
Veterinary Medicine., C. V. Sc. &  
A. H., A.N.D. University of  
Agriculture & Technology,  
Kumarganj, Ayodhya,  
Uttar Pradesh, India

**Naveen Kumar Singh**

Assistant Professor, Veterinary  
Clinical Complex, C. V. Sc. & A. H.,  
A.N.D. University of Agriculture &  
Technology, Kumarganj, Ayodhya,  
Uttar Pradesh, India

**Rama Kant**

Assistant Professor, Department of  
Veterinary Medicine., C. V. Sc. &  
A. H., A.N.D. University of  
Agriculture & Technology,  
Kumarganj, Ayodhya,  
Uttar Pradesh, India

**Jitendra Pratap Singh**

Assistant Professor, Department of  
Veterinary Medicine., C. V. Sc. &  
A. H., A.N.D. University of  
Agriculture & Technology,  
Kumarganj, Ayodhya,  
Uttar Pradesh, India

**Rakesh Kumar Gupta**

Guest Faculty, Department of  
Veterinary Pathology, C. V. Sc. &  
A. H., A.N.D. University of  
Agriculture & Technology,  
Kumarganj, Ayodhya,  
Uttar Pradesh, India

**Debasish Niyogi**

Professor, Department of  
Veterinary Pathology, C. V. Sc. &  
A. H., A.N.D. University of  
Agriculture & Technology,  
Kumarganj, Ayodhya,  
Uttar Pradesh, India

**Corresponding Author:****Ashish Pandey**

M. V. Sc., Department of  
Veterinary Medicine, C. V. Sc. & A.  
H., A.N.D. University of  
Agriculture & Technology,  
Kumarganj, Ayodhya,  
Uttar Pradesh, India

## Effect of feeding *Embilica officinalis* (Amla) on milk quality in cattle affected with subclinical mastitis

**Ashish Pandey, Satya Vrat Singh, Naveen Kumar Singh, Rama Kant, Jitendra Pratap Singh, Rakesh Kumar Gupta and Debasish Niyogi**

DOI: <https://doi.org/10.22271/phyto.2020.v9.i2u.11024>

**Abstract**

*Embilica officinalis* or Indian gooseberry is perhaps the single most often mentioned herb in "Charak Samhita", the Ayurvedic medicine literature (500 BC). Ayurveda, which is the oldest health system in the world, appreciates and uses amla to treat a host of diseases and promote positive health. Thirty two animals positive for subclinical mastitis were randomly divided into four different groups containing 8 animals each and supplemented with various doses of deseeded fresh amla. Changes in milk yield, fat%, solids not fat, total solids and total bacterial count were studied. Supplementation of amla @ 250 gram and 200 gram increased the milk yield by 14.58% and 14.28%, significantly decreased total bacterial count but did not have any significant changes in fat%, total solids and solid not fat, although an increase in fat was recorded. Supplementation at 150 gram too increased milk yield, decreased total bacterial count but the changes were statistically non significant. In unsupplemented group, an increase in somatic cell count, total bacterial count and decline in milk yield was recorded indicative of development of mastitis. Thus, amla can be used as an alternate to conventional therapy and can be supplemented to cattle in routine feeding especially in areas where it is surplus.

**Keywords:** Subclinical mastitis, cattle, *Embilica officinalis*, milk quality

**Introduction**

*Embilica Officinalis* or Indian gooseberry, Amla is a gift of nature to mankind with wide distribution in tropical and subtropical areas, and has therapeutic potential against harmful diseases (Kulkarni *et al.* 2018) [21]. The Sanskrit name, Amlaki, translates as the Sustainer or The Fruit where the Goddess of Prosperity Resides. It is perhaps the single most often mentioned herb in "Charak Samhita", the Ayurvedic medicine literature (500 BC). In Hindu religious mythology the tree is worshipped as the Earth Mother as its fruit is considered to be so nourishing as to be the nurse of mankind Ayurveda, which is the oldest health system in the world, appreciates and uses amla to treat a host of diseases and promote positive health. The active ingredient that has significant pharmacological action in amla is designated by Indian scientist as "Phyllembin". The fruit is rich in quercetin, phyllaemblic compounds, gallic acid, tannins, flavonoids, pectin, and vitamin C and also contains various polyphenolic compounds. A wide range of phytochemical components including terpenoids, alkaloids, flavonoids, and tannins have been shown to possess useful biological (Kim *et al.* 2005; Arora *et al.* 2003 and Kumar *et al.* 2018) [18, 2, 20].

*Embilica Officinalis* is known to possess potent antibacterial activity against *Staphylococcus aureus* (Reghu and Ravindra, 2010; Dhale and Mogle, 2011; Patil *et al.* 2012, Varghese *et al.* 2013) [3, 7, 30, 46], *Escherichia coli*, *Klebsiella pneumoniae*, *K. ozaenae*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Salmonella typhi*, *S. paratyphi* A, *S. paratyphi* B and *Serratia marcescens* (Saeed and Tariq, 2007) [35]. *Embilica* is an excellent antioxidant and free radical scavenger (Bhattacharya *et al.* 2002; Anila and Vijayalakshmi, 2003; Hazara, 2010) [3, 1, 12]. Vitamin C in *Embilica Officinalis* accounts for approximately 45-70% of the antioxidant activity (Scartezzini *et al.* 2006) [38]. Various investigators have reported that the fruits of *E. officinalis* have immune-modulatory activity (Rama Rao, 1998; Sairam *et al.* 2002; Ganju *et al.* 2003; Srikumar *et al.* 2007) [33, 36, 9, 43]. The anti-inflammatory properties of *E. officinalis* is also established by numerous workers (Golechha *et al.* 2014; Yokozawa, 2000, Santosh Kumar *et al.* 2013) [37]. In addition it has a hepatoprotective effect (Pramyothin *et al.* 2006; Bhattacharya *et al.* 2000) [32]. Pharmacological research reports on amla reveals its analgesic

(Sharma *et al.* 2004) <sup>[40]</sup>, anti-tussive (Nosalova *et al.* 2003) <sup>[29]</sup>, anti-atherogenic (Kumar *et al.* 2013) <sup>[19]</sup>, adaptogenic (Muruganandam *et al.* 2002) <sup>[26]</sup>, gastroprotective (Chatterjee *et al.* 2010), nephro-protective (Yokozawa *et al.* 2007) <sup>[49]</sup>, neuro-protective (Vasudevan and Parle, 2007) <sup>[47]</sup> and anticancer (Madhuri, 2008) <sup>[22]</sup> properties. The potential biological properties of *Embilica Officinalis* remain untrapped in the animal health sector. The complete package of antibacterial, antioxidant, anti inflammatory, free radical scavenging, hepato-protective properties in one wonder drug can thus be of immense use in the prevention and treatment of innumerable health disorders, mastitis being one of them. Mastitis is globally recognised as the most common and costly disease affecting dairy herds causing heavy financial losses to dairy industries by reducing yield and milk quality, and associated treatment costs (Mushtaq *et al.* 2018) <sup>[27]</sup>. Subclinical mastitis or hidden mastitis is the most commonly occurring form of mastitis that ensues when the animal's immunity or udder immunity gets compromised and mastitogens proliferate and succeed in establishing themselves to some extent. Subclinical mastitis causes considerable changes in milk composition and serum, which may contribute to the impaired immune defence (Megalia *et al.* 2001).

There is dearth of literature regarding the effect of amla in treatment of subclinical mastitis. Therefore, the present research focuses on the effect of feeding crushed raw amla on the changes in milk composition and production status in subclinically affected cows.

#### Materials and methods

The present study was conducted from September 2015 to January 2016 on 32 cross breed lactating cows that were screened positive for subclinical mastitis.

#### Selection of Animal

The cross breed lactating cows aged between 3-5 years in their first to third lactation and managed under identical managerial conditions were included in this study. The physical and clinical examination of all cows was carried out during lactation as suggested by Schalm *et al.* (1971) <sup>[39]</sup> for exclusion of abnormality of udder and teat (e.g. size shape, consistency as udder possessing lumps, oedema, atrophy, fibrosis and misplacement of teats, blint teats induration etc). Such examination was continued until final selection of those cows, which revealed any visible clinical signs. (Radostits *et al.* 2007)

**Place of Work:** College of Veterinary Science & Animal Husbandry

#### Collection of *E. Officinalis* fruits:

Fresh fruits of amla were collected from the university farm. The composition of the variety used has already been established by Pathak *et al.* (2003). The fruit extract was prepared by the method described by Dash *et al.* 2011.

**Variety of Amla Used:** Narendra Amla-10

#### Screening of animals

Milk samples were collected aseptically from each quarter before on day 0 and thereafter on days 3, 7 and 15. The udder was initially washed with antiseptic solution for visible debris and teat ends were scrubbed with cotton soaked in 70% ethanol and allowed to air dry. The first 3-4 streak of milk was discarded and next 10 ml of milk was collected into

separate clean, dry & sterilized test tubes. The tubes were stoppered and brought immediately to the laboratory in ice packed container for mastitis screening tests. Milk was subjected to battery of tests namely California mastitis test, white side test, Mastrip test and somatic cell count. Somatic cell count of milk was performed as per the method described by Schalm *et al.* (1971) <sup>[39]</sup>.

#### Experimental design

Thirty two animals positive for subclinical mastitis were supplemented with various doses of deseeded fresh amla. All the cows were randomly divided into four different groups containing 8 animals each. Animals of group 1 were given crushed deseeded fresh amla at the dose rate 250 gm (A-250) for 15 days. Cows of group II were supplemented with crushed deseeded fresh amla at the dose rate of 200 gm (A-200) for period as in group 1. Cows in group III were supplemented with crushed deseeded fresh amla at the dose rate of 150 gm (A-150) for period as in group 1. Group IV cows were left untreated as control. Milk samples were collected before and after supplementation for determining the alterations in milk quality- milk yield, fat (%), solid not fat and total solids. The total bacterial count (TBC) was carried out as per the standard method (Griffin *et al.* 1977).

#### Statistical analysis

Statistical analysis was done using t-test as described by Snedecor and Cochran (1994) <sup>[42]</sup>.

#### Result

Animals in A -250 group supplemented with amla @ 250 gm PO for 15 days showed 75% recovery. Two animals remained in sub clinically affected state. A significant decrease in the mean CMT, WST and MST score points were recorded after treatment. A similar trend was noticed in SCC ( $\times 10^5$ ) also as 0 days count decreased significantly from  $5.78 \pm 0.89$  to  $2.86^* \pm 0.95$  after the treatment (Table-1).

A significant decrease in total bacterial count was observed in group 1 animals from  $4.4 \times 10^5 \pm 1.13$  cfu/ml to  $2.3 \times 10^5 \pm 0.93$  cfu/ml (Table-2). The milk yield increased significantly from  $8.23 \pm 0.96$  lts to  $9.43 \pm 0.82$  with increase by 14.58% (Table-3). An increase in fat (%)  $4.23 \pm 1.13$  to  $4.56 \pm 1.72$ , solid not fat and total solids was noticed but was statistically insignificant (Table -4).

Animals in A-200 group showed 62.5% recovery. Three animal remained sub clinically affected. The mean CMT score of  $2.50 \pm 0.19$  on day 1 decreased significantly to  $1.85^* \pm 0.31$  after treatment. The mean WST and MST score point too decreased but was statistically non significant. A declining trend was noticed in SCC also as 0 days count decreased significantly from  $6.25 \pm 0.78$  to  $4.24^* \pm 0.54$  after the treatment (Table -1).

A significant decrease in total bacterial count was observed in group II animals from  $4.0 \times 10^5 \pm 0.96$  cfu/ml to  $2.7 \times 10^5 \pm 1.07$  cfu/ml (Table-2). The milk yield increased significantly from  $7.92 \pm 0.94$  lts to  $8.80 \pm 1.86$  lts with an increase of 14.28% (Table-3). An increase in fat% from  $4.43 \pm 1.35$  to  $4.58 \pm 1.17$ , solid not fat and total solids was noticed but was statistically insignificant (Table-4).

Animals in group III (A-150) supplemented with amla @ 150 gm PO for 15 days showed 25% recovery (table-1). Six animal remained sub clinically affected. A non significant decrease in the mean CMT, WST and MST score points were recorded after treatment. The SCC also decreased significantly from  $6.24 \pm 1.84$  to  $5.16 \pm 1.88$  after the treatment. (Table -1). A

significant decline in total bacterial count was observed in group I animals from  $3.8 \times 10^5 \pm 1.19$  cfu/ml to  $3.1 \times 10^5 \pm 1.04$  cfu/ml (Table-2). The milk yield increased insignificantly from  $8.28 \pm 1.23$  lts to  $8.46 \pm 1.22$  (Table-3). An increase in fat% ( $4.70 \pm 1.52$  to  $4.82 \pm 1.21$ ), solid not fat and total solids was noticed but was statistically non significant (Table-4).

In control un supplemented i.e. group IV no recovery was observed. All the animals remained sub clinically affected. The mean CMT score of  $2.44 \pm 0.24$  on day 1 increased non significantly to  $2.72 \pm 0.22$ . An increase in mean WST and MST score points and SCC were also observed but was statistically insignificant (Table -1). An increase in total bacterial count was recorded from  $4.2 \times 10^5 \pm 1.24$  cfu/ml to  $5.1 \times 10^5 \pm 1.16$  cfu/ml (Table-2). The milk yield decreased insignificantly from  $8.98 \pm 1.42$  lts to  $7.82 \pm 1.86$  (Table-3).

Amongst the amla treated groups maximum recovery was obtained in Group I (@ 250gm PO OD for 15 days) followed by group II (@ 200gm PO OD for 15 days) and group III (@ 150gm PO OD for 15 days). The recovery recorded in Amla treated groups can be attributed to the synergistic effect of the bioactive principles i.e. antibacterial property antibacterial, anti-inflammatory and immunopotentiating property of *Emblca Officinalis*. Golechha *et al.* (2014) at the dose of 700mg/kg, exhibited maximum anti-inflammatory activity in all experimental models and the effects were comparable to that of the standard anti-inflammatory drugs. Savala *et al.*, 2012 prescribed the concentration for human dosage as 0.75 gms/kg body weight.

## Discussion

Sharma *et al.* (2014) [41] had earlier recorded better udder health of cows in groups supplemented with polyherbal preparation of which *Emblca officinalis* was a component, as indicated by decline in SCC, prevalence of subclinical mastitis, and incidence of clinical mastitis can be attributed to their better immune status due to polyherbal supplementation. The changes in mastitis markers CMT score point, WST score point, MST score point and Somatic cell count reflect the severity of mastitis. The decline observed reflects the recovery. An increase in the severity of mastitis leads to a significant increase in milk SCC (Dang *et al.* 2010) [6] and hence widely used as marker to determine the mammary health and quality of milk (Swain *et al.* 2014; Eberhart *et al.* 1982) [44, 8]. Depending on the size of the inflammation one may observe a reduction in milk yield and unfavourable changes in the milk composition (Jozwik *et al.* 2004) [15]. Milk production loss per affected quarter due to sub-clinical mastitis was estimated to be 17.6% on average (Graaf and Dwinger, 1996) [11]. Mungube *et al.* (2005) [25] recorded a reduction by 1.2%, 6.3% and 33% in quarters with CMT scores 1+, 2+ and 3+ scores respectively. The increase in milk

production should thus indicate suppression of inflammatory changes and improvement in udder health.

The varied literature on the medicinal plant reveals that the plant *E. officinalis* have the antibacterial (Hossain *et al.* 2012; Philip *et al.* 2012; Usha *et al.* 2012) [13, 31, 45], antifungal (Hossain, *et al.* 2012; Mehmood *et al.* 1999) [13, 23] and antioxidant properties (Golechha *et al.* 2012) [10]. The potent anti inflammatory activity of *Emblca Officinalis* was earlier established by Golechha *et al.* 2014; Mishra, 2004; Yokozawa, 2007 [49]; Kumar *et al.* 2013) [19]. Reghu and Ravindra, (2010) [3] had revealed the inhibitory activity of Amla extracts to the growth of *S. aureus*. Saeed and Tariq, (2007) [35] also observed potent antibacterial activity of aqueous infusion and decoction of *Emblca officinalis* against *Escherichia coli*, *Klebsiella pneumoniae*, *K. ozaenae*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Salmonella typhi*, *S. paratyphi A*, *S. paratyphi B* and *Serratia marcescens*. Varghese *et al.* (2013) [46] also observed maximal antibacterial activity against *S. aureus* for the fruit extract, comparable with that of the commonly used antibiotics having varied mode of action and were of the view that none of the antibiotics were superior to the *Emblca* extracts against *Pseudomonas*. The antimicrobial properties of *P. emblica* were also studied by Srikumar *et al.* (2007) [43]. The bactericidal activity of *E. officinalis* could be attributed to the bioactive compounds present in *E. officinalis* namely flavonoids, phenols, saponins, and tannins such as emblicanin A and B which could be effectively employed as effective chemotherapeutic agents in antibacterial treatment and therapy (Javale and Sabnis, 2010; Jyothi and Rao, 2011) [14, 16]. *Emblca* is an excellent antioxidant and free radical scavenger. The antioxidant activity of fruits of *E. officinalis* has been traced to its tannoid principles both *in vitro* and *in vivo* (Bhattacharya *et al.* 2002) [3]. The potent antioxidant properties of Amla has also been confirmed by Hazara, (2010) [12]. The free radical-scavenging activity of plants extract and individual compounds in the extracts of *P. emblica* were also recorded in several *in vitro* studies (Kumar *et al.* 2006; Nampoothiri *et al.* 2011). Vitamin C in *Emblca Officinalis* accounts for approximately 45-70% of the antioxidant activity (Scartezzini, *et al.* 2006) [38]. Chawla and Kaur (2004) [5] showed that the elevated content of antioxidants in the blood of cows to a considerable degree protected them from metabolic diseases, including mastitis. Although ruminants can synthesize vitamin C in the liver and it is not considered to be an essential nutrient for healthy cattle, a large reduction in plasma vitamin C concentration was reported in lactating cow with artificially induced mastitis (Weiss *et al.* 2004) [48]. Khopde *et al.* (2001) [17] reported that ascorbic acid and other polyphenols present in the natural formulation of amla showed much superior antioxidant activity compared to their equivalent amounts in pure isolated form.

**Table 1:** Screening test profile before and after treatment

Group	CMT		WST		MST		SCC x10 <sup>5</sup> cells/ml	
	Before Treatment	After Treatment	Before Treatment	After Treatment	Before Treatment	After Treatment	Before Treatment	After Treatment
I	2.37±0.18	1.52*±0.26	2.52±0.19	1.66*±0.38	1.87±0.45	1.26*±0.52	5.78±0.89	2.86*±0.95
II	2.50±0.19	1.85*±0.31	2.25±0.35	1.67*±0.14	1.87±0.81	1.38*±0.83	6.25±0.78	4.24*±0.54
III	2.51±0.19	2.12±0.22	2.18±0.80	1.86±0.88	1.98±0.58	1.72±0.48	6.24±1.84	5.16*±1.88
IV	2.44±0.24	2.72±0.22	1.98±0.21	2.12±0.84	1.84±0.51	2.28±0.26	6.48±0.80	7.16±0.48

\*Values differs significantly  $P < 0.05$



**Table 2:** Total bacterial count before and after treatment

	Before treatment (x 10 <sup>5</sup> cfu/ml)	After Treatment (x 10 <sup>5</sup> cfu/ml)
Group-1 (A-250)	4.4 ±1.13	2.3* ±0.93
Group-2 (A-200)	4.0±0.96	2.7* ±1.07
Group-3 (A-150)	3.8±1.19	3.1 ±1.04
Group-4(un supplemented)	4.2±1.24	5.1 ±1.16

\*Values differs significantly  $P < 0.05$

**Table 3:** Milk yield (lt.) before and after treatment in sub clinical mastitis positive cows

Days	Group I PHM (250gm)	Group II PHM (200gm)	Group III (150gm)	Group IV (untreated group)
0 day	8.23±0.96	7.92±0.94	8.28±1.23	8.98±1.42
5 <sup>th</sup> day	8.42±0.64	8.13±0.06	8.30±1.07	8.64±1.51
10 <sup>th</sup> day	9.33±0.22	8.57±0.97	8.24±1.06	8.33±1.22
15 <sup>th</sup> day	9.43*±0.82	8.80*±1.86	8.46±1.22	7.82*±1.86
% variation	14.58	14.28	3.38	-12.91

**Table 4:** Changes in values of FAT, SNF, TOTAL SOLIDS before and after therapy

	I		II		III		IV	
	Before	After	Before	After	Before	After	Before	After
Fat (%)	4.23±1.13	4.56±1.72	4.43±1.35	4.58±1.17	4.70±1.52	4.82±1.21	4.63±1.43	4.90±1.27
SNF (%)	7.90±1.26	8.16±1.32	8.18±1.74	8.23±1.87	8.20±1.63	8.26±1.52	8.13±1.81	8.63±1.92
Total solids (%)	12.38±2.23	12.92±2.24	12.20±2.02	12.26±2.17	12.86±1.73	13.08±1.96	12.86±2.11	13.13±2.61

## Conclusion

*Embilica officinalis* can be potentially incorporated in feeding schedule of lactating cattle to reduce the incidence of disease especially mastitis through improving nonspecific immunity of periparturient cows especially in areas where *Embilica officinalis* is in abundance, but it require further studies on standardization, formulation and mode of delivery to explore more beneficial effects. Plant products such as *A. indica* could be used as an anti-inflammatory and antibacterial arsenal against the disease to reduce the burden of antibiotics.

## Acknowledgement

The current study is a part of M.V.Sc thesis submitted to the ANDUAT, Kumarganj, Ayodhya. The Authors acknowledge Department of Veterinary Medicine, Veterinary Clinical Complex, College of Veterinary Science and Animal Husbandry, ANDUAT, Kumarganj, Ayodhya, India for providing all necessary facilities for this study.

## Funding Agency

All facilities require for the study were provided Department of Veterinary Medicine, College of Veterinary Science and Animal Husbandry, ANDUAT, Kumarganj, Ayodhya, India.

## Declaration of Interest

The authors declare that this work has not been submitted anywhere for publication.

## Conflict of interest

The authors report no conflict of interest.

## References

- Anila L, Vijayalakshmi NR. Antioxidant action of flavonoids from *Mangifera indica* and *Embilica officinalis* in hypercholesterolemic rats. *Food Chem.* 2003; 83:569-574.
- Arora S, Kaur K, Kaur S. Indian medicinal plants as a reservoir of protective phytochemicals. *Teratog Carcinog Mutagen.* 2003; (11):295-300.
- Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Effect of bioactive tannoid principles of *Embilica officinalis* on ischemia-reperfusion-induced oxidative stress in rat heart. *Phytomedicine.* 2002; 9:171-174.
- Chatterjee A, Chattopadhyay S, Sandip, Bandyopadhyay K. Biphasic effect of *Phyllanthus emblica* extract on NSAID-Induced ulcer: An anti-oxidative trail weaved with immunomodulatory effect. *Evidence-Based Complementary and Alternative Medicine.* 2011, 1-13.
- Chawla R, Kaur H. Plasma antioxidant vitamin status of periparturient cows supplemented with alpha-tocopherol and beta-carotene. *Animal Feed Science and Technology.* 2004; 11(4):279-285.
- Dang AK, Mukherjee J, Kapila S, Mohanty AK, Kapila R, Prasad S. *In vitro* phagocytic activity of milk neutrophils during lactation cycle in Murrah buffaloes of different parity. *J Anim. Physiol. Anim. Nutr.* 2010; 94:706-711.
- Dhale DA, Mogle UP. Phytochemical screening and antibacterial activity of *Phyllanthus emblica* (L.). *Sci. Res. Report.* 2011; 1(3):138-142.
- Eberhart RJ, Hutchinson LJ, Spencer SB. Relationships of bulk tank somatic cell counts to prevalence of intramammary infection and to indices of herd production. *J Food Prot.* 1982; 45:1125-1128.
- Ganju LD, Karan S, Chanda S, Srivastav KK, Sawhney RC, Selvamurthy W. Immunomodulatory effects of agents of plant origin. *Biomed. Pharmacol. Ther.* 2003; 57:296-300.
- Golechha M, Bhatia J, Arya D. Studies on effects of *Embilica officinalis* (Amla) on oxidative stress and cholinergic function in scopolamine induced amnesia in mice. *J Environ. Biol.* 2012; 14:3395-100.
- Graaf T, Dwinger RH. Estimation of milk production losses due to sub-clinical mastitis in dairy cattle in Costa Rica. *Preventive Veterinary Medicine.* 1996; 26:215-222
- Hazara B. Comparative study of the antioxidant and reactive oxygen species scavenging properties in the extracts of the fruits of *Terminalia chebula*, *Terminalia bellerica* and *Embilica officinalis*. *BMC Complementary and Alternative Medicine.* 2010; 5:10-20.
- Hossain MM, Mazumder K, Hossen SMM, Tanmy TT, Rashid MJ. *In vitro* studies on antibacterial and

- antifungal activities of *Embllica officinalis*. Int. J Pharma. Sci. Res. 2012; 3:1124-1127.
14. Javale P, Sabnis S. Antimicrobial properties and phytochemical analysis of *Embllica officinalis*. Asian J Exp. Biol. Sci. 2010; 1:91-95.
  15. Jozwik A, Sliwa-Jozwik A, Strzałkowska N, Krzyzewski J, Kołataj A. Relationship between somatic cell count, level of GSH, milk yield and its chemical composition. Medycyna Weterynaryjna. 2004; 60(11):1215-1217.
  16. Jyothi KS, Subba B. Screening of antibacterial activity of *Embllica officinalis* fruits. Pharmacology online. 2011; 3:848-852.
  17. Khopde SM, Priyadarsin KI, Mohan H, Gawandi VB, Satav JG, Yakhmi JV *et al.* Characterizing the antioxidant activity of amla (*Phyllanthus emblica*) extract. Cur. Sci. 2001; 81(2):185-190.
  18. Kim HJ, Yokozawat K, Tohda C, Rao TP, Juneja LR. Influence of Amla (*Embllica Officinalis Gaertnl*) on hypercholesterolemia and lipid peroxidation in cholesterol-fed rats. J Nutr Sci Vitaminol. 2005; 51:413-418.
  19. Kumar A, Haque S, Sahay S, Singh KK, Roy BK. Bacteriology and antibiogram of bovine mastitis in Ranchi and its vicinity. Int. J Agril. Sc & Vet. Med. 2013; 2:64-68.
  20. Kumar S, Kumar D, Yadav PK, Bal LM, Singh BP. Amla as phytogetic feed additive for efficient livestock production. Journal of Pharmacognosy and phytochemistry. 2018; 7(4):1030-1036.
  21. Kulkarni KV, Ghurghure SM. Indian gooseberry (*Embllica officinalis*): complete pharmacognosy review. Int J Chem Studies. 2018; 2:5-11.
  22. Madhuri S. Studies on estrogen induced uterine and ovarian carcinogenesis and effect of ProImmu in rat, PhD thesis, Jabalpur, MP, RDVV, 2008.
  23. Mehmood Z, Ahmed I, Mohammad F, Ahmed S. Indian medicinal plant a potential source for anticandidal drugs. Pharm. Biol. 1999; 37:237-242.
  24. Mishra LC. Scientific basis of Ayurvedic therapies, second ed., CRC press, 2004.
  25. Mungube EO, Tenhagen BA, Regassa F, Kyule MN, Shiferaw Y, Kassa T *et al.* Reduced milk production in udder quarters with subclinical mastitis and associated economic losses in crossbred dairy cows in Ethiopia. Tropical Animal Health and Production. 2005; 37:503-512.
  26. Muruganandam AV, Kumar V, Bhattacharya SK. Effect of polyherbal formulation, EuMil, on chronic stress-induced homeostatic perturbations in rats. Indian Journal of Experimental Biology. 2002; 40(10):1151-1160.
  27. Mushtaq S, Shah AM, Shah A, Lone AH, Hussain A, Hassan QP *et al.* Bovine mastitis: An appraisal of its alternative herbal cure. Microbial pathogenesis. 2018; 114:357-361.
  28. Nampoothri SV, Prathapan A, Cherian OL, Ragh KG, Venugopalan VV, Sundaresan A. In vitro antioxidant and inhibitory potential of *Terminalia belerica* and *Embllica officinalis* fruits against LDL oxidation and key enzymes linked to type 2 diabetes. Food and Chem. Toxicol. 2011; 49:125-131.
  29. Nosalova G, Mokry J, Hasan KM. Antitussive activity of the fruit extract of *Embllica officinalis* Gaertn, (Euphorbiaceae). Phytomedicine. 2003; 10:583-589.
  30. Patil SG, Deshmukh AA, Padol AR, Kale DB. *In vitro* antimicrobial activity of *Embllica officinalis* fruit by tube dilution method. Int. J Toxicol. Appl. Pharmacol. 2012; 2(4):49-51.
  31. Philip J, John S, Iyer P. Antimicrobial Activity of *Aloevera barbedensis*, *Daucus carota*, *Embllica officinalis*, Honey and *Punica granatum* and formulation of a health drink and salad, Malays. J Microbiol. 2012; 8:141-147.
  32. Pramyothin P, Samosorn P, Pongshompoo S, Chaichantipyuth C. The protective effects of *Phyllanthus emblica* Linn. extract on ethanol induced rat hepatic injury. J Ethnopharmacol. 2006; 107(3):361-4.
  33. Rama RR. Interpretation of AIDS with traditional immunity therapy, Proceedings of international seminar on complimentary medicine in AIDS. MAPA. 1998; (20):28-35.
  34. Reghu HS, Ravindra P. Antimicrobial activity and phytochemical study of *Phyllanthus emblica* Linn. Int. J Pharm. Studies Res. 2010; 1(1):30-33.
  35. Saeed S, Tariq P. Antibacterial activities of *Embllica officinalis* and *Coriandrum sativum* against gram negative urinary pathogens. Pak. J Pharm. Sci. 2007; 20(1):32-35.
  36. Sairam MD, Neetu B, Yogis B, Anju B, Dipti P. Cytoprotective and immunomodulating properties of Amla (*Embllica officinalis*) on lymphocytes: An in vitro study. J Ethnopharmacol. 2002; (8):10-15.
  37. Santoshkumar J, Manjunath S, Pranavkumar MS. A study of anti-hyperlipidemia, hypolipidemic and anti-atherogenic activity of fruit of *Embllica officinalis* (Amla) in high fat fed Albino Rats. International Journal of Medical Research and Health Sciences. 2013; 2(1):70-77.
  38. Scartezzini PF, Antognoni MA, Raggi F, Sabbioni C. Vitamin C content and antioxidant activity of the fruit and of the Ayurvedic preparation of *Embllica officinalis* Gaertn. J Ethnopharmacol. 2006; 104(1, 2):113-8.
  39. Schalm OW, Carrol EJ, Jain NC. Bovine Mastitis. Lea and Febiger. Philadelphia, 1971, 128-129.
  40. Sharma SK, James B, Perianayagam AJM, Christina. Evaluation of anti-pyretic and analgesic activity of *Embllica officinalis* Gaertn, Journal of Ethnopharmacology. 2004; 95:83-85.
  41. Sharma A, Shiv P, Singh Y, Bishisth R. Effect of polyherbal preparation supplementation on immunity and udder health of periparturient Karan-Fries crossbred dairy cows. Journal of Applied Animal Research. 2014; 42(2):217-221
  42. Snedecor GW, Cochran WG. Statistical Methods. 8th ed., Iowa State University Press. New Delhi. 1994, 26-102.
  43. Srikumar R, Parthasarathy NJ, Shankar EM, Manikandan S, Vijayakumar R, Thangaraj R. Evaluation of the growth inhibitory activities of Triphala against common bacterial isolates from HIV infected patients. Phytoter. Res. 2007; 21(5):476-480.
  44. Swain DK, Kushwaha MS, Kaur M, Mohanty AK, Dang AK. Formation of NET, phagocytic activity, surface architecture, apoptosis and expression of toll like receptors 2 and 4 (TLR2 and TLR4) in neutrophils of mastitic cows. Vet. Res. Commun. 2014; 38(3):209-219.
  45. Usha NP, Bibu KJ, Jose S, Nair AMC, Nair GK, Nair ND. Antibacterial activity of successive extracts of some medicinal plants against field isolates of *Pasteurella multocida*. Indian J Ani. Sci. 2012; 82:1146-1149.
  46. Varghese LS, Alex N, Ninan MA, Soman S, Jacob S. Evaluation of *in vitro* antibacterial activity whole plant (fruits, seeds, stem, leaves and roots) of *Embllica*

- Officinalis* Gaertn. International Journal of Ayurvedic and Herbal Medicine. 2013; 3(6):1420-1425.
47. Vasudevan M, Parle M. Memory enhancing activity of Anwalachurna (*Emblica officinalis* Gaertn.): An Ayurvedic preparation. Physiology and Behaviour. 2007; 91(1):46-54.
48. Weiss WP, Hogan JS, Smith KL. Changes in vitamin C concentrations in plasma and milk from dairy cows after an intramammary infusion of *Escherichia coli*. J of Dairy Sci. 2004; 87:32-37.
49. Yokozawa T, Kim HY, Kim HJ, Tanaka T, Sugino H, Okubo T *et al.* Amla (*Emblica officinalis* Gaertn.) Attenuates Age- Related Renal Dysfunction by Oxidative Stress. Journal of Agricultural and Food Chemistry. 2007; 55:7744-7752.